Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Sprint Bioscience AB (publ) develops pharmaceutical products in the areas of cancer and metabolism in Sweden, Europe, the United States, and Asia. It engages in developing VPS34, a drug candidate for the treatment of various types of cancer; and PETRA01, a drug candidate for the treatment of cancer. The company also focuses on research of...
Company Valuation
Considering past and projected metrics, the stock is moderately 'expensive' compared to its peers. In particular, the stock is reasonably priced on P/E.
Target Price
The average target price of SPRINT.ST is 2.5 and suggests 52% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to in
Buy
Sell